Pre-Clinical Work and Animal Studies Underway, and Protocols for Clinical Studies Under Development Irvine, CA - (NewMediaWire) - February 25, 2019 - Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that it intends to expand the scope of its sponsored research in Nigeria to include neurological conditions, including Post-Traumatic Stress Disorder (PTSD). CBIS and its research collaborator are currently investigating the potential beneficial effects of cannabidiol on oro-bucco-lingual dyskinesias, oxidative stress, and psychosis using animal studies and a clinical trial. CBIS recently announced receipt of U.S. Patent Number 9,763,991 for Compositions of Cannabinol (CBN) for Treatment of Various Neurobehavioral Disorders, Sleep Deprivation (Insomnia), Anxiety Disorders, and PTSD, among other target indications.The invention relates to a composition for use in the treatment of neurobehavioral disorders utilizing various Cannabis plant extracts comprising CBN preferably with other constituents of this plant for such use and a method for the extraction of plants. The plants or plant parts may for instance be derived from Cannabis Sativa and/or Cannabis Indica and/or Cannabis ruderalis and/or other elements, and mixtures thereof. The plant extracts derived showed particularly beneficial effects against Sleeping Disorders, in particular Insomnia, PTSD, and anxiety disorders including Attention Deficit Hyperactivity Disorder (ADHD).The animal studies are well underway and should be completed in the coming months. This study is important in a country like Nigeria where movement disorders are still common because the relatively inexpensive conventional antipsychotics are still widely in use. Movement disorders are known to be more common in patients on the conventional antipsychotics, though they have also been reported in the atypical antipsychotics. It is therefore pertinent to continue to search for new and better forms of management of this difficult to manage movement disorder in psychotic patients. CBIS has entered into an initial, one-year Research Collaboration Agreement with Stellenbosch University. CBIS and Stellenbosch University intend to jointly develop and investigate the use of Cannabinoids to treat chronic pelvic pain disorder/chronic prostatitis, and potentially other indications. Stellenbosch University (SU) is one of the oldest Universities in South Africa. The research is being conducted in South Africa and Nigeria.Cannabis Science is aggressively expanding the Company’s network of research centers. Negotiations are ongoing with several academic institutions in the United States and internationally to establish new, collaborative research agreements. These contracts will focus on several indications, and are expected to expand the research funded, and directed by the Company. In addition, Cannabis Science will develop multi-center, clinical trial networks with cannabinoid drug development.“We are encouraged with the preliminary results from our pre-clinical work and animal studies in Nigeria,” stated Mr. Raymond C. Dabney, CBIS’ President, CEO, and Co-founder. “The research may be of use in other movement disorders, such as Huntington’s Disease, Tourette’s Syndrome, Cerebral Palsy, and Dystonia. These could be related through the neurotransmitter, dopamine, modulated by the CB1 receptors. While we will continue our research in regard to oro-bucco-lingual dyskinesias, oxidative stress, and psychosis, we believe there is an opportunity to expand our research in Nigeria to include PTSD. Specifically, we will develop a protocol for a PTSD clinical study immediately and begin this study as soon as possible. This will allow the Company to leverage our patent for compositions of cannabinol (CBN), as well as our expertise with other cannabinoids.”“Our work in Nigeria, while independent of our research collaborations in the U.S., contributes significantly to the Global Consortium we launched last year,” added Mr. Dabney. The Cannabis ...
Seattle, WA - (NewMediaWire) - February 25, 2019 - CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Aleafia Health Inc. (TSX-V: ALEF) (OTCQX: ALEAF) (FRA: ARAH). The vertically-integrated licensed producer with a clinic network and over 50,000 patients, was named as the 2019 TSX Venture 50 top performing company of the year. The TMX Group’s annual performance awards are based on three equally weight criteria, including market capitalization growth, share price appreciation and trading volume.The TSX Venture exchange has become a popular place for cannabis companies to list their shares, particularly after Canada legalized recreational cannabis last year, but 2019 was the first year that a cannabis company topped its annual performance rankings.The award demonstrates the company’s increasing popularity in the space. Over the past 52 weeks, the company’s stock price rose from a low of $0.47 to a high of $4.70 before settling at its current levels of around $2.37, making it a popular stock for active traders interested in the cannabis industry. As such, daily trading volume averaged roughly 1.42 million shares over the past three months, providing significant liquidity for investors.Research Proves a Strong CatalystAleafia Health’s stock reached all-time highs back in late-September when it partnered with Cronos Group Inc. to study the effects of medical cannabis on insomnia and daytime sleepiness. Under the terms of the deal, Cronos Group would provide funding for the study, which would be conducted by doctors at Aleafia’s health clinics. The company also formally launched Aleafia Labs to focus on these research projects.The company’s stock also moved sharply higher when it announced positive results from its benzodiazepine study. After conducting a study with 146 patients, the company reported that 45.2 percent of patients stopped consuming benzodiazepines—as a sedative or anti-anxiety medication—following a medical cannabis prescription. The patients further reported decreased daily distress due to their medical condition.These research projects leverage the company’s wholly-owned network of more than 20 Canabo Medical Clinics with over 50,000 patients. With the largest medical cannabis dataset in the world, the company enables researchers to validate cannabis science, product teams to innovate, and management to build a strong portfolio of intellectual property. The division had already generated $612,000 in revenue by the third quarter of 2018.Appealing to Both Traders & InvestorsMany cannabis stocks appeal to active traders that look for important catalysts and price movements, but only a fraction of these companies are also attractive on a fundamental basis to long-term investors. Aleafia Health is an existing licensed producer with an experienced management team, 98,000 kilograms per year of production capacity expected this year, and a network of medical cannabis clinics with over 50,000 patients.The company already generates tangible revenue from its medical cannabis clinics, research activities and supply agreement with CannTrust Holdings Inc.. After merging with Emblem Corp., the company has amassed a significant production footprint that it’s expanding further through strategic investments around the world. At the same time, its massive cannabis dataset provides an invaluable competitive advantage.Currently, the company trades with a market capitalization of about $375 million, which is lower than many other licensed producers. As the company scales up production and research activity, investors may become increasingly interested in the growing revenue and cash flow. The R&D activity could also pave the way towards valuable revenue streams from licensing, which may help boost revenue and margins over the long-term.Click Here to Download Aleafia Health Inc.’s Investor PresentationLooking AheadAleafia Health Inc. (TSX-V: ALEF) (OTCQX: ALEAF) (FRA: ARAH) represents a compelling ...
eHealth, Inc. (NASDAQ: EHTH), the nation's leading private online health insurance exchange, is correcting misstatements regarding non-GAAP net income and non-GAAP net income per diluted share for the ...
Statement Highlights: New developments in identifying and treating the increased risk of premature heart disease in children and teens with certain medical conditions associated with increased cardiovascular risk are discussed in a scientific statement from the American Heart Association. Obesity and severe obesity are now considered significant risk factors for an increased risk of cardiovascular disease in children and teens. Embargoed until 4 a.m. CT / 5 a.m. ET Mon. Feb. 25, 2019 (NewMediaWire) - February 25, 2019 - DALLAS - Obesity and severe obesity in childhood and adolescence have been added to the list of conditions that put children and teens at increased risk for premature heart disease, according to a new scientific statement from the American Heart Association published in the Association’s journal Circulation. The statement provides an overview of current scientific knowledge about managing and treating the increased risk of atherosclerosis and early heart disease, in children and teens with type 1 or 2 diabetes, familial high cholesterol, congenital heart disease, childhood cancer survivorship and other conditions. Atherosclerosis is the slow narrowing of the arteries that underlies most heart diseases and stroke. “Parents need to know that some medical conditions raise the chances of premature heart disease, but we are learning more every day about how lifestyle changes and medical therapies that can lower their cardiovascular risk and help these children live their healthiest lives,” said Sarah de Ferranti, M.D., M.P.H., chair of the writing group for the statement and chief of the Division of Cardiology Outpatient Services at the Boston Children’s Hospital in Massachusetts. For example, there are treatments for familial high cholesterol – a group of genetic disorders that affect how people process cholesterol which can lead to extremely high cholesterol levels – that can help children and teens with this disorder live a normal lifespan. The statement is an update of a 2006 scientific statement and adds obesity and severe obesity to the list of conditions that put children and teens at increased risk of cardiovascular diseases and reviews new treatments for previously discussed conditions. Severe obesity and obesity are now considered moderate risk and at-risk conditions respectively because research shows they significantly increase chances of developing heart disease later in life. A study of almost 2.3 million individuals followed for over 40 years found the risks of dying from a cardiovascular disease were two to three times higher if their body weight as adolescents had been in the overweight or obese category compared to youth with normal weight. Effective treatments for obesity have proven elusive, but in general, a gradual approach to weight loss is generally required, incorporating improvements in dietary quality, fewer calories, more physical activity, meal replacements, medical therapy and/or bariatric surgery depending on the severity of the excess adiposity. Other significant changes to the statement since 2006 include: The elevation of Type 2 diabetes to a high-risk condition because of its association with additional cardiovascular risk factors such as high blood pressure and obesity. The expansion of the risks of premature heart disease associated with treatments for childhood cancers. Co-authors are Julia Steinberger, M.D., M.S.(Co-Chair); Rebecca Ameduri, M.D.; Annette Baker, R.N., M.S.N., C.P.N.P.; Holly Gooding, M.D., M.Sc.; Aaron S. Kelly, Ph.D.; Michele Mietus-Snyder, M.D.; Mark M. Mitsnefes, M.D., M.S.; Amy L. Peterson, M.D.; Julie St-Pierre, M.D., Ph.D.; Elaine M. Urbina, M.D., M.S.; Justin P. Zachariah, M.D., M.P.H.; and Ali N. Zaidi, M.D. Author disclosures are on the manuscript. Additional Resources: After Feb. 25, view the manuscript online. Obesity as young adult sets stage for heart disease, stroke Podcast - Children and Familial Hypercholesterolemia Age at cancer diagnosis may affect the risk of death from heart disease Follow AHA/ASA news on Twitter @HeartNews ### The ...
Boston, MA - (NewMediaWire) - February 22, 2019 - Zoom Telephonics, Inc. (OTCQB: ZMTP) (“Zoom” or the “Company”), a leading producer of cable modems and other communication products, announced today that it expects to release its financial results for the fourth quarter and year ended December 31, 2018, after the close of market on Thursday, February 28, 2019. The Company will host a conference call at 4:30 p.m. Eastern Time that afternoon to discuss the results.Conference Call DetailsThursday, February 28, 2019 – 4:30 p.m. ETParticipant Dial-In Numbers:(United States): (866) 393-7958(International): (706) 643-5255Please dial-in five minutes prior to the start time of the call and provide the operator with the conference ID of 2280997.A slide presentation will accompany management’s remarks and will be accessible five minutes prior to the start of the call via the following link: www.zoomtel.com/SQ418. A recording of the call will also be made available afterwards through the investor information section of the Company’s website. About Zoom TelephonicsZoom Telephonics, Inc. designs, produces, markets, and supports cable modems and other communication products. The Company’s worldwide Motorola license agreement includes cable modems and gateways, DSL modems and gateways, cellular modems and routers and sensors, and other Internet and network products. For more information about Zoom and its products, please visit www.zoomtel.com/investor and www.motorolanetwork.com.MOTOROLA and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license.Investor Relations Contact: Adam Prior, Senior Vice-President The Equity Group Inc. Phone: 212-836-9606 Email: aprior@equityny.com
Madrid, Spain - (NewMediaWire) - February 22, 2019 - Vodafone Spain has become today the first operator in the world to make 5G standard calls from 5G mobile phones, after connecting the first smartphones to the 5G network with the specifications of the 3GPP NSA (Non Stand Alone) standard, which will be used later on commercial launch. The mobile phones have been connected to the Vodafone 5G network deployed in the center of Barcelona.The operator managed to implement various services, including several video calls to Spanish journalists via the commercial network between Barcelona and Madrid with a Huawei terminal. In mobile tests, download speed of up to 1.7Gbps were achieved. Both the smartphones used and the Vodafone 5G network meet the specifications of the Non Stand Alone 5G - 3GPP Release 15 standard, approved last year.Pilot projectVodafone already achieved in February 2018 the first 5G connection in the world between Castelldefels and Madrid, although on that occasion, the connection consisted of a videoconference between a PC connected to a 5G standard test network and a 4G mobile.It was also a pioneer in starting the deployment of a pre-commercial 5G network in Spain. In July 2018, it installed the first 5G NSA nodes in central areas of Madrid, Barcelona, Seville, Malaga, Bilbao and Valencia. This deployment began only days after acquiring 90 MHz of contiguous spectrum in the 3.7 GHz band.Vodafone Spain has already started several pilots in these cities to test possible 5G applications in the future. This is the case of the Connected Surgeon Project, in which a specialist surgeon guides, without being physically present and in real time, another surgeon who is operating in any operating room. Thanks to 5G technology, it is possible to transfer practical knowledge at critical moments. This pilot is part of a broad collaboration agreement that will make the Hospital Clínic de Barcelona the first 5G hospital in the country.John Leung John.leung@wmglobal.com
Learn From Two Dozen Commercial Litigation Finance Experts Across Many Disciplines New York, NY - (NewMediaWire) - February 22, 2019 - DealFlow Events is pleased to announce the agenda for The Litigation Funding Forum 2019coming up April 4 in New York City.The complete agenda and panel speakers: https://litigationfundingforum.com/agenda/Here is just some of the information our slate of experts will cover during this must-attend event:Latest trends in the litigation funding marketplaceChallenges facing legal counsel with litigation fundingBenefits to investors in litigation fundingGrowth prospects in the marketplace: Leveling the legal playing fieldWhat counsel should look for in identifying the right litigation financing firm for clientsHow litigation funders determine cost to ROIContracts and risk managementLitigation funding in patent and intellectual property casesThe conference keynote speaker is New York State Sen. Rob Ortt, who introduced the Litigation Funding Act.Whether you are a funder, an attorney or a litigation finance consultant, The Litigation Funding Forum 2019 is a can’t-miss event. Panels of experts are ready to answer your questions regarding litigation finance, while exploring the latest legal trends, best practices and insights to maximize the benefits of litigation finance while avoiding challenges that have tripped up others.Corporate sponsors of The Litigation Funding Forum 2019 include Validity Finance, RRBB Accountants + Advisors, and Armadillo Financial Partners.Learn more about the forum at https://litigationfundingforum.com/.This event will likely sell out. Get your tickets today at https://litigationfundingforum.com/tickets/.Questions? Contact DealFlow at (516) 876-8006 or email Charlie Napolitano at charlie@dealflow.com.About DealFlowWhen it comes to the business of finance, the tag line “A DealFlow Event” is widely recognized as a symbol of quality. We’ve produced over 200 conferences, seminars, and webcasts on a variety of financial topics over the last 16 years. These events are the signature programs in their respective markets, offering high-quality content and unequaled professional networking opportunities.For more information about our events business, visit www.dealflowevents.com.For more information about some of our other projects, visit www.dealflow.com.Media Contact Charlie Napolitano charlie@dealflow.com (516) 876-8006 ext. 20
Growing retailer adds store in Davenport, IADavenport, IA - (NewMediaWire) - February 22, 2019 - American Freight Furniture and Mattress is opening its first Quad City-area store on February 22, 2019. The new Davenport store is 35,000 square feet and is located at 1010 E. Kimberly Rd. Davenport, IA 52807 next to Stefanini and Harbor Freight Tools. This store will create 6-10 new jobs.“We’re excited to open our first Iowa store in the heart of the Quad City region,” said Karl Finley, Vice President. “Our new location will be a great discount furniture option for Davenport, IA and surrounding areas. We offer a huge selection of living room furniture, bedroom sets, dining sets, and mattresses at affordable prices. Our free layaway, same-day delivery, and a flexible payment option make buying furniture easy. Take it home today for $50 with low, easy payments. Visit our Davenport, IA store today to see why American Freight is the best choice for quality furniture and mattresses.” American Freight has always made it our mission to save customers money on quality furniture and mattresses while providing excellent customer service. We are able to do this by purchasing products directly from manufacturers and selling in warehouse-style stores. By cutting out the middle man and keeping the overhead low, American Freight is able to offer the lowest prices with quality service. This successful formula has made American Freight Furniture and Mattress one of the fastest-growing furniture retailers in the United States.Weekly store hours for the new Davenport, IA location during Tax Season are as follows:· Monday-Friday (10am-8pm)· Saturday (10am-7pm)· Sunday (12pm-5pm)Our offerings include: living room – sofas, loveseats, sectionals, recliners, accent chairs, and coffee and end tables; bedroom – three, five, and seven-piece bedroom suites from Twin through King; dining room – five and seven-piece sets; mattresses – premiere foam, hybrid (innerspring and foam), innerspring and pocketed coil sets in all sizes; and accessories to complete your home selections. Customers can pay for items in full or take advantage of our payment plan options. We offer a 100% approved layaway program and no credit needed payment plans to help make your home comfortable and complete. Same-day delivery and pick up is available for all in-stock items.About American FreightSince 1993, American Freight Furniture and Mattress has been helping customers save money on quality furniture and mattresses. American Freight offers flexible payment options including free layaway and take it home today for $50 with low, easy payment plans (see www.americanfreight.com/50 for details). With over 160 stores and over 2 million satisfied customers, American Freight continues to grow while our mission remains the same: sell the best for less every day while delivering excellent customer service. See for yourself - shop at one of our 160+ stores or online and discover why American Freight is the place to go for all your home furnishing needs. To learn more about American Freight Furniture and Mattress, visit www.americanfreight.com/ , follow us on Twitter @AmericanFreight and on Facebook at www.facebook.com/AmericanFreightFurniture.Media Contact: Taylor Janszen 740.363.2222 | tjanszen@americanfreight.us
Coconut Creek FL - (NewMediaWire) - February 22, 2019 - NutraFuels, Inc. fka NutraLife BioSciences, Inc. (OTCQB: NTFU) (NTFU) and Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI) (together, the “Companies”), in a joint venture, today announce that analytical tests on Hemp-derived CBD oil processed by PBI’s Ultra Shear Technology™ (UST) platform confirm that: (i) UST processing results in the development of a true CBD oil nanoemulsion, and (ii) CBD is neither lost nor modified during the UST process (> 99% recovery).The proprietary UST platform combines ultra-high pressure with extreme shearing forces to create very small, nano-scale mixtures of fluids that otherwise do not mix, resulting in a highly stable homogenized solution called nanoemulsions.Dr. Vera Gross, Senior Scientist R&D at PBI, commented: “To determine if the UST process resulted in a loss or modification of CBD during processing, we enlisted the help of our collaborator NutraFuels, Inc. NTFU has an FDA-inspected, highly-qualified analytical laboratory with state-of-the-art equipment and well-trained chemists with years of experience in laboratory testing.”For many oil-based nutritional and therapeutic products, such as CBD-infused nutraceuticals, nanoemulsions offer superior water solubility and increased bioavailability for improved absorption. Consequently, there is a significant need to develop reliable, scalable methods to process CBD oil into high-quality nanoemulsions, with minimal loss of CBD during the process. Mr. Cooper Dodd, an R&D Scientist at NTFU, said: “Using a powerful laboratory method called HPLC to measure the concentrations of CBD and potential impurities, we determined that no appreciable amount of CBD was lost during the UST process. These results compare well to our standard processing method of ultrasonication, which can carry a risk of measurable loss of CBD, and sometimes create the appearance of impurities if not performed properly. While there is more work to be done, as a nutraceutical manufacturer with products already on the market, we see these results as a robust leap towards better optimization of our CBD-enhanced products.”Dr. Gross, Director of Applications Development from PBI, added: “To determine if UST processing of CBD oil generates true nanoemulsions, we asked an independent, university-affiliated laboratory to determine the size of oil droplets in post-UST processed material using a universally-accepted sizing method called DLS. Their results showed that post-UST processed oil droplets were approximately 65 nm in size, well within the range of 20-200 nm generally accepted as defining a true nanoemulsion (Nano- and Microscale Drug Delivery Systems, 2017).”Professor Keith Warriner, Professor of Food Science at the University of Guelph, and a recognized expert in the cannabis industry, commented: “The data disclosed today on UST-generated nanoemulsions of CBD oil are very impressive. Creating nanoemulsions of CBD oil with full preservation of CBD throughout the process, while not generating impurities, remains a significant challenge in the industry. These data offer great promise to the future.”Professor Warriner continued: “Although there is great excitement over CBD-infused edibles and beverages, and rightfully so, I believe that CBD-infused topicals may be an even greater market for CBD products in the near future. However, to be successful, it is imperative that topicals be highly stable, bioavailable and readily absorbent nanoemulsions. After a review of the data released today, the UST process appears to be a leading candidate to fill that need.”Dr. Bradford A. Young, Chief Commercial Officer of PBI, commented: “We were very excited to share the news just last week of PBI’s visually obvious successful production of water-soluble CBD Oil. However, the addition of these scientific validations of our successful achievement of creating nanoemulsions by the UST platform, and our preservation of CBD levels all the way through to the finished product are frankly the crowning touch to the news of these ...
